Lihir Medical Centre
Quick facts
Marketed products
- R2-Total targeted treatment with azithromycin
- R3-Total community treatment with azithromycin
- R3-Total targeted treatment with azithromycin
Phase 3 pipeline
- Albendazole on Day 1 · Infectious Disease / Parasitology
Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cytoskeletal structure and causing paralysis and death. - Azithromycin on Day 1 · Infectious Disease
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and halting bacterial growth. - Azithromycin on Day 8 · Infectious Disease
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby stopping bacterial growth. - Diethylcarbamazine on day 1 · Parasitic Infection / Tropical Medicine
Diethylcarbamazine immobilizes and kills microfilariae by interfering with their neuromuscular function, making them susceptible to immune clearance. - Ivermectin on Day 1 · Infectious Disease / Parasitology
Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites, causing paralysis and death.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Lihir Medical Centre
What are Lihir Medical Centre's marketed drugs?
Top marketed products include R2-Total targeted treatment with azithromycin, R3-Total community treatment with azithromycin, R3-Total targeted treatment with azithromycin.
What is Lihir Medical Centre's pipeline?
Lihir Medical Centre has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Albendazole on Day 1, Azithromycin on Day 1, Azithromycin on Day 8, Diethylcarbamazine on day 1.